DOCSLIB.ORG

Reigniting Recruitment

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reigniting Recruitment a Publication of the HIV Vaccine Trials Network VOLUME 4, ISSUE 1 | JULY, 2012 REIGNITING RECRUITMENT IN THIS ISSUE photo by Sid Niazi ARTICLES 02 Probing the Diversity of Vaccine Elicited HIV-1 Antibodies: Informed by the 18 Social and Behavioral Science in Clinical Trials of Biomedical HIV Prevention RV144 Correlates Analysis Interventions 03 Assays to Probe the Humoral Response 22 HVTN Annual Network Award Winners 06 Turning up the Heat in Miami 24 HVTN Protocols 07 Orlando HVTN 505 Study Site: From Challenges to Accomplishments CALENDAR [back cover] 10 Assessing Mucosal Immune Responses in HIV Vaccine Trials 13 Highlights from Recent HVTN Publications Probing the Diversity of Vaccine Elicited HIV-1 Antibodies: Informed by the RV144 Correlates Analysis Georgia D. Tomaras RV144, a trial conducted by the U.S. Military HIV Research IgG antibody responses (ie, ADCC and nAbs) might corre- Program and the Thai Ministry of Health, was the first HIV-1 late with decreased risk of infection if present with low levels vaccine study in which a modest efficacy (31.2%) of HIV-1 of Env IgA (higher levels of Env IgA seem to counteract the vaccination was shown. The study regimen consisted of a beneficial effects of IgG). Thus, the balance of antibody types, canarypox prime expressing Gag, Pro, and gp120 (ALVAC- and the interactions among them -- particularly in those with HIV), and a gp120 boost (AIDSVAX® B/E). These results different Fc receptor binding properties -- merits further study were published in the New England Journal of Medicine in to determine if specific Env antibody isotypes influence the 2009.1 level of vaccine efficacy. A concerted effort by an international consortium of investiga- The results from the RV144 correlates analysis have signifi- tors, led by Dr. Barton F. Haynes of Duke University, set out cantly informed our understanding of how to analytically to determine if any immune variables correlated with infection probe the HIV-1 vaccine elicited antibody responses, and risk in the RV144 trial. In the initial phase of the studies, there generated several leading hypotheses that are critical to test was an open call to measure vaccine-elicited immune responses in future HIV-1 vaccine candidates. Measurements of the re- on RV144 samples. In the next phase, a selected set of immune sponse rates and magnitudes of V1V2 IgG antibodies and Env variables, chosen from the pilot study results, were formally IgA binding antibodies elicited by different vaccine regimens tested as primary immune variables for the correlates analysis (different vector, adjuvant, and Env immunogen formulations) of RV144. are important for understanding the broad applicability of these findings -- ie, whether these correlates can be confirmed The RV144 correlates analysis yielded 2 immune correlates with other regimens. of risk: V1V2 IgG antibodies correlated with decreased risk Durability of HIV-1 Env Immune Responses of infection, while HIV-1 Env IgA antibodies correlated with increased risk of infection in the vaccine arm (higher One of the most overarching lessons from RV144, indepen- Env IgA levels seemed to have abrogated the vaccine effect, dent of the immune correlates results, comes from the observa- but the risk of infection in this group was not higher than 2 tion that there was decreased vaccine efficacy over time. This in the placebo group). The combined results of the original waning of vaccine efficacy corresponds to decreasing vaccine- and correlate studies galvanized the HIV-1 vaccine field, and specific immune responses (anti-Env antibody titers). Thus, the have influenced the direction of subsequent protocols testing measurement of the durability of immune responses (antibody HIV-1 vaccine candidates. Notably, these correlates of HIV-1 half-life) is a critical component for evaluating improvements infection risk from RV144 are not necessarily surrogates of in HIV-1 vaccine strategies going forward. protection nor mechanistic correlates. However, toward the goal of identifying the types of immune responses an effica- Antibody Responses to Circulating vs. Vaccine Strain cious vaccine should elicit, the RV144 study has provided key HIV-1 Env hypotheses to test in further HIV-1 vaccine trials. The 2 correlates of risk identified in RV144, along with cor- Key Hypotheses Generated by RV144 responding secondary analyses, highlight an important feature for assessing vaccine efficacy. The measurements that correlated The RV144 correlates analysis evaluated 6 primary variables: most strongly with infection risk were not those against the the binding of plasma IgA antibodies to Env, the avidity of vaccine strain Env in the boost, but rather antibodies against IgG antibodies for Env, antibody-dependent cellular cyto- cross-clade responses: The strongest statistical correlate was toxicity (ADCC), HIV-1 neutralizing antibodies (nAbs), the the association of risk with IgA responses to the C1 region in binding of IgG antibodies to variable regions 1 and 2 (V1V2) gp120 of circulating strain in Thailand (CRF01AE). Moreover, of the gp120 Env, and the level of Env-specific CD4+ T cells.2 IgG responses to the V2 region of CRF01AE Env significant- In addition to the 2 identified immune correlates of risk ly correlated with decreased risk of infection among the differ- (V1V2 IgG and HIV-1 Env IgA), analysis of the 6 primary ent clades of V2 responses tested in the peptide microarray variables using interaction models suggested that functional assay (Gottardo, Montefiori et al., unpublished).2 This Continued on page 5... 2 JUNE 2012 VOLUME 4:1 | HVTNEWS Assays to Probe the Humoral Response Georgia D. Tomaras There are several categories of assays used to examine the diverse humoral response to vaccination: 1) validated assays for HIV-1 vaccine endpoints, 2) qualified and/or standardized assays and 3) assays for research and development. Validated assays are currently used in the first line assessment of HIV-1 vaccine trials. Qualified and/or standardized assays are utilized to generate hypotheses and further characterize vaccine im- munogenicity. Assays for research and development are more exploratory in nature and are not suitable as a vaccine study endpoint, but can provide substantial insight into the com- plexity and potential functionality of vaccine elicited immune responses. VALidated ASSAYS FOR HIV-1 Vaccine V= Variable Region C=Constant Region H=Heavy Chain L=Light Chain ENDPOINTS Structure of the antibody: The variable regions (VH, VL) contain the an- Neutralizing Binding Antibodies tigen binding sites; the Fc region mediates the effector activity (eg, neutral- ization); the constant regions present in the heavy chain define the isotype Currently validated assays include the measurement of of antibody (IgA, IgD, IgE, IgG, and IgM) and subclass (eg, IgG1-4). neutralizing antibodies categorized as Tier 1 or Tier 2 neutralization using the TZM-bl assay. Validated assays to clinical trials include the measurement of both monomeric assess binding antibody responses (IgG and IgA) by ELISA IgA (mIgA) and dimeric IgA (dIgA) that will be extended to the and multiplex bead technology are in place and can measure analysis of human mucosal samples. Moreover, the analysis magnitude and breadth of vaccine elicited responses. The goal of IgA responses and IgG subclasses, and the respective ratios of ongoing validation efforts include improving upon existing between different types of antibodies, may provide insights assays (eg, validation of A3R5 neutralization assays) and to into the role of different adjuvants/priming on the quality of the select additional binding and functional assays most relevant humoral responses. for vaccine evaluation. Antibody Epitope Mapping (Linear and QUALIFIED AND StandardiZED Conformational) A potentially important characteristic of antibodies is their ASSAYS breadth of binding to multiple HIV-1 clades (Group M, Clade IgG Subclasses, Isotypes, and Mucosal A, B, C, AE, etc.). Recent assay developments include the measurement of diverse HIV-1 Envs resulting in a single score Antibodies for magnitude and breadth. The linear epitope specificities are Antibody isotypes and IgG subclasses (IgG1-IgG4) are measured using either binding antibody assays with specific currently being measured in response to vaccination. The epitopes (eg, V2, C1, alanine scanning mutants) or through an rationale for measuring antibody isotypes and subclasses is HIV-1 multiclade peptide microarray that can fully measure that they provide insights into potential functional responses. multiclade gp160 epitope specificity. Conformational epitopes IgG1 and IgG3 are considered to be the most functional of (eg, CD4BS, CD4i, C1, and N-glycan dependent epitopes) can the subclasses in that they have been associated with HIV-1 be determined through differential binding to wild type pro- neutralization, complement fixation, FcR binding and antibody teins/scaffolds with and without mutation(s) that alter confor- dependent cellular cytotoxicity / cell mediated virus inhibition mational binding sites, or through competitive binding assays (ADCC/ADCVI). lgA antibodies at mucosal sites have been with monoclonal antibodies of known specificities (eg, A32 correlated with protection in exposed, uninfected subjects and monoclonal antibodies [mAb] blocking). studies in NHPs have indicated a potentially protective role for mucosal antibody responses as well as antibody effector functions and IgA memory B cells. Current assays in human Continued on page 4... www.hvtn.org
Load more

Recommended publications
  • The CAB Bulletin HIV Vaccines and the Community
    The CAB Bulletin HIV Vaccines and the Community Planning for PrEP My First Time By Genevieve Meyer, HVTN Community Education Unit By Dino Martino, On November 23rd, 2010, the results of the iPrEx study were released. The Orlando, FL CAB member. 2,499-person study demonstrated that a daily dose of oral Truvada®, (a With nervous excitement I accepted combination of two antiretroviral medications, emtricitabine and tenofovir) could the offer to attend my first HVTN reduce new infections of HIV in gay men, transwomen and other men who have conference. As a member of the sex with men (MSM) by an average of 43.8%. The HVTN salutes the sponsors, newly formed CAB in Orlando, this study team, and volunteers in the 11 sites throughout Brazil, Ecuador, Peru, South Africa, Thailand and the United States who contributed to this study’s success. was another “first time” opportu- nity in a series of events that I have The results of the iPrEx study have added increased vigor to the HVTN’s search had the pleasure to be a part of in for a safe and effective HIV vaccine. One central question being asked at the HVTN support of the work of the HVTN. right now is what these results mean for participants in HVTN 505, a study which is also enrolling MSM and transwomen who are at risk of contracting HIV. As a pharmacist for nearly two de- cades, scientific conferences are not The Network has set up a working group to solicit feedback from community new to me; still, each one brings stakeholders about possible changes to HVTN 505 based on the iPrEx results.
    [Show full text]
  • Antibody Fc Effector Functions and Igg3 Associate with Decreased HIV-1 Risk
    RESEARCH ARTICLE The Journal of Clinical Investigation Antibody Fc effector functions and IgG3 associate with decreased HIV-1 risk Scott D. Neidich,1 Youyi Fong,2,3,4 Shuying S. Li,2,3 Daniel E. Geraghty,5 Brian D. Williamson,4 William Chad Young,2 Derrick Goodman,1 Kelly E. Seaton,1 Xiaoying Shen,1 Sheetal Sawant,1 Lu Zhang,1 Allan C. deCamp,2 Bryan S. Blette,6 Mengshu Shao,2 Nicole L. Yates,1 Frederick Feely,1 Chul-Woo Pyo,3 Guido Ferrari,1,7,8 HVTN 505 Team,9 Ian Frank,10 Shelly T. Karuna,3 Edith M. Swann,11 John R. Mascola,12 Barney S. Graham,12 Scott M. Hammer,13 Magdalena E. Sobieszczyk,13 Lawrence Corey,3 Holly E. Janes,2,3,4 M. Juliana McElrath,3 Raphael Gottardo,2,3 Peter B. Gilbert,2,3,4 and Georgia D. Tomaras1,7,8,14 1Duke Human Vaccine Institute, Duke University, Durham, North Carolina, USA. 2Statistical Center for HIV/AIDS Research and Prevention, 3Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 4Department of Biostatistics, University of Washington, Seattle, Washington, USA. 5Clinical Research Division, Fred Hutchinson Cancer Research Center, Seattle, Washington, USA. 6Department of Biostatistics, University of North Carolina Gillings School of Global Public Health, Chapel Hill, North Carolina, USA. 7Department of Surgery and 8Department of Molecular Genetics and Microbiology, Duke University, Durham, North Carolina, USA. 9The HVTN 505 Team is detailed in the Supplemental Acknowledgments. 10Division of Infectious Diseases, Perelman School of Medicine, University of Pennsylvania, Philadelphia Pennsylvania, USA. 11Division of AIDS and 12Vaccine Research Center, National Institute of Allergy and Infectious Diseases (NIAID), NIH, Bethesda, Maryland, USA.
    [Show full text]
  • HIV/AIDS Technologies: a Review of Progress to Date and Current Prospects
    Working Paper No.6 HIV/AIDS Technologies: A review of progress to date and current prospects COMMISSIONED BY: aids2031 Science and Technology Working Group AUTHORED BY: KEITH ALCORN NAM Publications Disclaimer: The views expressed in this paper are those of the author(s) and do not necessarily reflect the official policy, position, or opinions of the wider aids2031 initiative or partner organizations aids2031 Science and Technology working group A review of progress to date and current prospects October 2008 Acronyms 3TC lamivudine ANRS Agènce Nationale de Récherche sur la Sida ART Antiretroviral therapy ARV Antiretroviral AZT azidothymidine or zidovudine bDNA branched DNA CDC US Centers for Disease Control CHER Children with HIV Early Antiretroviral therapy (study) CTL Cytotoxic T-lymphocyte D4T stavudine DSMB Data and Safety Monitoring Board EFV Efavirenz ELISA Enzyme Linked Immunosorbent Assay FDC Fixed-dose combination FTC Emtricitabine HAART Highly Active Antiretroviral Therapy HBAC Home-based AIDS care HCV Hepatitis C virus HPTN HIV Prevention Trials Network HSV-2 Herpes simplex virus type 2 IAVI International AIDS Vaccine Initiative IL-2 Interleukin-2 LED Light-emitting diode LPV/r Lopinavir/ritonavir MIRA Methods for Improving Reproductive Health in Africa trial MSF Médecins sans Frontières MSM Men who have sex with men MVA Modified vaccinia Ankara NIH US National Institutes of Health NRTI Nucleoside reverse transcriptase inhibitor NNRTI Non-nucleoside reverse transcriptase inhibitor OBT Optimised background therapy PCR Polymerase
    [Show full text]
  • Safety and Immunogenicity of a Recombinant Adenovirus Serotype
    C S & lini ID ca A l f R o e l s Fuchs et al., J AIDS Clin Res 2015, 6:5 a e n a r r u c o h J AIDS & Clinical http://dx.doi.org/10.4172/2155-6113.1000461 ISSN: 2155-6113 Research Research Article Open Access Safety and Immunogenicity of a Recombinant Adenovirus Serotype 35-Vectored HIV-1 Vaccine in Adenovirus Serotype 5 Seronegative and Seropositive Individuals Jonathan D Fuchs1,2,*, Pierre-Alexandre Bart3, Nicole Frahm4, Cecilia Morgan4, Peter B Gilbert4, Nidhi Kochar4, Stephen C DeRosa4, Georgia D Tomaras5, Theresa M Wagner1, Lindsey R Baden6, Beryl A Koblin7, Nadine G Rouphael8, Spyros A Kalams9, Michael C Keefer10, Paul A Goepfert11, Magdalena E Sobieszczyk12, Kenneth H Mayer13, Edith Swann14, Hua-Xin Liao5, Barton F Haynes5, Barney S Graham15 and M Juliana McElrath4 for the NIAID HIV Vaccine Trials Network 1Population Health Division, San Francisco Department of Public Health, San Francisco, CA, USA 2Department of Medicine, University of California, San Francisco, San Francisco, USA 3Centre Hospitalier Universitaire Vaudois, Lausanne, Switzerland 4Vaccine and Infectious Disease Division, Fred Hutchinson Cancer Research Center, Seattle, WA, USA 5Human Vaccine Institute, Duke University, Durham, NC, USA 6Division of Infectious Disease, Brigham and Women’s Hospital, Boston, MA, USA 7Laboratory of Infectious Disease Prevention, New York Blood Center, New York, NY, USA 8The Hope Clinic, Division of Infectious Diseases, Emory University, Atlanta, GA, USA 9Infectious Diseases Division, Vanderbilt University School of Medicine, Nashville,
    [Show full text]
  • (Sexpro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States
    Title: Development and Validation of the Personalized Sexual Health Promotion (SexPro) HIV Risk Prediction Model for Men Who Have Sex with Men in the United States. Authors Title Email Site Hyman Scott [email protected] Bridge HIV, San Francisco Department of (corresponding) Public Health, San Francisco, California Eric Vittinghoff [email protected] University of California, San Francisco, San Francisco, CA Risha Irvin [email protected] John’s Hopkins School of Medicine, Baltimore, Maryland Albert Liu [email protected] Bridge HIV, San Francisco Department of Public Health, San Francisco, CA LaRon Nelson [email protected] University of Rochester. Rochester, New er.edu York Carlos Del Rio [email protected] Emory University, Atlanta, Georgia Manya Magnus [email protected] George Washington University, Washington, District of Columbia Sharon [email protected] Columbia University, New York, New Mannheimer York Sheldon Fields [email protected] Charles Drew School of Medicine, Los Angeles, California Irene Kuo [email protected] George Washington University, Washington, District of Columbia Steve Shoptow [email protected] University of California, Los Angeles, California Beatrice [email protected] Instituto de Pesquisa Clinica Evandro Grinsztejn Chagas (IPEC), Rio de Janeiro, Brazil Jorge Sanchez [email protected] Asociacion Civil Impacta Salud y Educacion, Lima, Peru Steven [email protected] Fred Hutchinson Cancer Research Center, Wakefield Seattle, Washington Jonathan Fuchs [email protected]
    [Show full text]
  • Advancing Toward HIV-1 Vaccine Efficacy Through the Intersections of Immune Correlates
    Vaccines 2014, 2, 15-35; doi:10.3390/vaccines2010015 OPEN ACCESS vaccines ISSN 2076-393X www.mdpi.com/journal/vaccines Review Advancing Toward HIV-1 Vaccine Efficacy through the Intersections of Immune Correlates Georgia D. Tomaras 1,* and Barton F. Haynes 2 1. Departments of Surgery, Immunology, and Molecular Genetics and Microbiology, Duke Human Vaccine Institute, Durham, NC 27710, USA 2. Departments of Medicine and Immunology, Duke Human Vaccine Institute, Durham, NC 27710, USA * Author to whom correspondence should be addressed; E-Mail: [email protected]; Tel.: +1-919-681-5598; Fax: +1-919-684-5230. Received: 29 October 2013; in revised form: 29 October 2013 / Accepted: 9 December 2013 / Published: 27 December 2013 Abstract: Interrogating immune correlates of infection risk for efficacious and non-efficacious HIV-1 vaccine clinical trials have provided hypotheses regarding the mechanisms of induction of protective immunity to HIV-1. To date, there have been six HIV-1 vaccine efficacy trials (VAX003, Vaxgen, Inc., San Francisco, CA, USA), VAX004 (Vaxgen, Inc.), HIV-1 Vaccine Trials Network (HVTN) 502 (Step), HVTN 503 (Phambili), RV144 (sponsored by the U.S. Military HIV Research Program, MHRP) and HVTN 505). Cellular, humoral, host genetic and virus sieve analyses of these human clinical trials each can provide information that may point to potentially protective mechanisms for vaccine-induced immunity. Critical to staying on the path toward development of an efficacious vaccine is utilizing information from previous human and non-human primate studies in concert with new discoveries of basic HIV-1 host-virus interactions. One way that past discoveries from correlate analyses can lead to novel inventions or new pathways toward vaccine efficacy is to examine the intersections where different components of the correlate analyses overlap (e.g., virus sieve analysis combined with humoral correlates) that can point to mechanistic hypotheses.
    [Show full text]
  • The CAB Bulletin HIV Vaccines and the Community in This Issue: S
    The CAB Bulletin HIV Vaccines and the Community In this Issue: S. Africa CAB Retreat 2 CROI, GCAB Elections 3 Full Group Meeting 4-5 Honors & Awards 6-7 Calls & Announcements 8 From Unique Paths, Hope Takes Action— The Community Education Unit Reflections on the U.S./Swiss CAB Retreat Welcomes Niles Eaton By Reese Aaron Isbell, San Francisco CAB member Those who attended the Full Group Editor’s note on the CAB Retreats: From April 9-11, 2010 the CEU conducted a Meeting were introduced to the new U.S./Swiss CAB Retreat in Seattle, Washington. It was similar in format to the manager of the HVTN Community South African CAB retreat (see article by Siyabonga Nzimande in this issue): a Education Unit (CEU), Niles Eaton. train-the-trainer approach where CAB members worked with staff from the CEU to Niles may be new to the CEU but he present on topics such as an Introduction to Vaccinology, Introduction to Research is certainly not new to community Ethics, How to Read a Protocol, Vaccine-Induced Seropositivity, and many more. education or to the HVTN. Niles has Originally scheduled for June, 2010, the Latin American and Caribbean CAB spent the last seven years as a Clinical Retreat will take place in late Trials Manager and is incredibly 2010 or early 2011. “We all had two important knowledgeable about site operations We arrived separately and things in common: we were and structures. we ranged in age, race, Prior to joining creed and color. We were volunteers, and we were the HVTN, Niles gay, bi, straight, single, part of a world-wide effort to spent seven married (legally and eradicate HIV/AIDS.” years as a study one-day-soon-to-be).
    [Show full text]
  • HVTN CAB Bulletin HIV Vaccines and the Community
    HVTN CAB Bulletin HIV Vaccines and the Community In this Issue: Cape Town CAB Member Gets Published 2 HVAD Around the World 3 HVTN Conference Highlights 4 Welcome Jim Maynard! The Global CAB Welcomes David The Community Galetta as New Co-Chair Education Unit By Carrie Schonwald, Community Education Unit welcomed Jim Maynard as the new Associate Director We would like to announce the election of for Community Reverend David Galetta as International Development GCAB Co-Chair. David is currently the and Recruitment CAB Chairperson of the Desmond Tutu (overseeing both HIV Foundation in Cape Town, South Jim Maynard, Associ- ate Director for Com- Community Education Africa, where he has been a CAB member munity Development and Communications) since 2004. Rev. Galetta graduated with a & Recruitment. on May 16. Prior to the Post Graduate Diploma in International HVTN, Jim spent over Research Ethics from the University of Cape David Galetta, new international GCAB 12 years at the Fenway Institute (part Town in 2009 and serves on their Human Co-Chair. of Fenway Health) where he served as Sciences Research Ethics Committee as the Associate Director for Community …continues on page 7 Engagement. Jim brings a wealth of knowledge and experience gained during his years working with HVTN trials HVTN 505 Expands in Size and Scope as well as the HIV Prevention Trials Network (HPTN), the Microbicide Trials By Rick Church, Rich Trevino, Coco Alinsug, Jason Roberts (Community Network (MTN) and the Adolescent Trials members of the HVTN 505 protocol team) and Gail Broder, HVTN Community Network (ATN). His team leadership, Education Unit site perspective, depth of experience, and relentlessly positive energy will be a welcome addition the Core team.
    [Show full text]
  • Ongoing and Planned Trials of Preventive Hiv/Aids Vaccines (May 2012)
    ONGOING AND PLANNED TRIALS OF PREVENTIVE HIV/AIDS VACCINES (MAY 2012) Vaccine Sponsor/Funder/ Number of Status / Expected Trial 1 Phase Start Date Vaccine(s) 3 Trial Site 2 Clade abbreviation 3 Developer 2 Participants Completion Phase IIb (safety and efficacy) US (Nashville, TN; Birmingham, AL; Los Angeles, CA; San Francisco, CA; Denver, CO; Orlando, FL; Atlanta, VRC-HIVDNA016-00-VP; GA; Chicago, IL; DNA VRC-HIVADV014-00-VP Bethesda, MD; Boston, Ongoing / Expected HVTN 505 Phase IIb June 2009 DAIDS, NIAID, VRC 2,200 A, B, C Ad5 Prime: VRC-HIVDNA016- MA; New York, NY; 2013 00-VP Rochester, NY; Cleveland, OH; Philadelphia, PA; Dallas, TX; Houston, TX; Annandale, VA; Seattle, WA) Phase II (safety, adherence, acceptability, feasibility) ANRS 149 September DNA GTU-MultiHIV B DNA and Planned / Expected Phase II ANRS France (Créteil) 105 B LIGHT 2012 Lipopeptide LIPO-5 vaccines December 2014 ALVAC-HIV (vCP1521) U.S. Army Medical Canarypox Priming With VaxGen RV 305 Phase II March 2012 Research and Thailand (Chon Buri) 162 Ongoing / June 2013 gp120 B/E (AIDSVAX B/E) gp120 Materiel Command Boosting JS7 plasmid DNA and MVA62B vaccine Peru (Lima), US Ongoing, fully enrolled administered as (1) DNA January DNA DAIDS, GeoVax Labs (Birmingham, AL; San / August 2012, long- HVTN 205 Phase IIa at months 0 and 2 and 299 B 2009 Inc. Francisco, CA; New York, term follow-up Aug MVA MVA at months 4 and 6 NY; Seattle, WA) 2014 or (2) MVA at months 0, 2 and 6 Phase I/II and Ib (safety, adherence, acceptability, feasibility) January Modified Vaccinia Karolinska
    [Show full text]
  • Intentions to Use Pre-‐Exposure Prophylaxis Among Current Phase
    Intentions to use pre-exposure prophylaxis among current phase 2B preventive HIV-1 vaccine efficacy trial participants Jonathan D. Fuchs, MD, MPH,1,2 Magdalena E. Sobieszczyk, MD, MPH,3 Tamra Madenwald, MA, MPH,4 Doug Grove,5 Shelly T. Karuna, MD,4 Michele Andrasik, PhD,4 Adam Sherwat, MD,6 Gail Broder,4 Kenneth Mayer, MD,7 Beryl Koblin, PhD,8 and Scott Hammer, MD3 ; HVTN 505 Protocol Team 1San Francisco Department of Public Health 2Department of Medicine, University of California, San Francisco 3Dept. of Medicine, Division of Infectious Diseases, Columbia University College of Physicians and Surgeons 4HIV Vaccine Trials Network, Fred Hutchinson Cancer Research Center 5Statistical Center for HIV/AIDS Research and Prevention, Fred Hutchinson Cancer Research Center 6National Institutes of Allergy and Infectious Diseases, Bethesda, Maryland 7 Fenway Health and the Division of Infectious Diseases, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School 8Laboratory of Infectious Disease Prevention, Lindsley F. Kimball Research Institute, New York Blood Center Correspondence and request for reprints: Jonathan Fuchs, MD, MPH, San Francisco Department of Public Health, 25 Van Ness Ave. Suite 100, San Francisco, CA 94102, Email: tel. (415) 437-7409, fax (415) 431-7029; email: [email protected] Preliminary analyses were presented at AIDS Vaccine 2011, Bangkok, Thailand Conflicts of Interest and Source of Funding: The HVTN is supported through a cooperative agreement with the National Institute of Allergy and Infectious Diseases (AI068614AI068635) which supports TM, DG, SK, MA, and GB. JF is supported under a Division of AIDS CTU award (UO1AI069496); MS and SH are supported under CTU and CTSA awards (UO1AI69470, UL1RR024156); KM is supported under CTU awards (UM1AI069480-05 and UO1AI069412) and unrestricted research grant support from Gilead Sciences, Inc.
    [Show full text]
  • Px Wire: on HIV Prevention Research Volume 1 | No
    A Quarterly Update Px Wire: on HIV Prevention Research Volume 1 | No. 4 October–December 2008 and Phambili studies. The initial results of the Step study AVAC’s Take were published in November 2008 in the Lancet journal (Lancet, doi:10.1016/S0140-6736(08)61591-3). Greetings! This is the last issue of Px Wire in 2008—and what In the Step study, MRK-Ad5 had no overall benefit in terms a year it has been. The AIDS vaccine field has started to move Continues on back ahead with different goals and refined strategies in the wake of disappointing data from 2007. Multiple PrEP trials were launched or expanded, the microbicide field began to focus considerably At a Glance: Moving right along more on the implications of ARV-containing products, and the scale-up of male circumcision started in some countries. • An FDA panel of independent advisors recommended At the International AIDS Conference in August, and approval of the newly formulated female condom (FC2) in a provocative Lancet article (Lancet, doi:10.1016/S0140- in December, green-lighting the less expensive and 6736(08)61697-9) by WHO staff, including Kevin De Cock, physically streamlined second-generation product by director of the HIV/AIDS program, the notion of ARV the Female Health Company. Donors, governments and treatment as prevention seized the spotlight. This newly implementers should take advantage of this lower cost highlighted strategy will continue, we predict, to help shape option and take long overdue action to dramatically the field in 2009. increase access to and information about the female Also in 2009, AVAC will work with other prevention stakeholders condom as part of all HIV prevention and family to put the spotlight on HIV testing, which is the cornerstone planning programs.
    [Show full text]
  • The HVTN: Strategic Accomplishments of the First Decade and Beyond Tracey Day, Cecilia Morgan, Adi Ferrara, and Jim Kublin
    a Publication of the HIV Vaccine Trials Network VOLUME 3, ISSUE 2 | MARCH, 2012 Welcome to a new edition of the Our featured article in this issue is a HVTNews, the newsletter of the HIV look back at the Network’s achieve- Vaccine Trials Network. Our newslet- ments in 12 years of operation, and ter’s mission is to provide timely up- the impact it had on the HIV vaccine dates on the science of HIV vaccines, field. and the science of the HVTN. To that end, this issue features discussions that The search for an HIV vaccine is as include innate immunity studies at relevant and urgent today as it was at the HVTN, the possible impact of the the outset of the epidemic. We hope RV144 Correlates Analyses on future this issue gives you a glimpse of the vaccine trials, and the Network’s myriad ways in which the HVTN ongoing commitment to its study par- pursues our ultimate goal -- eradica- ticipants via our VISP testing service. tion with vaccination. Post RV144 Selection of gp120 [p. 8]. Figure of HIV-1 gp120 Env protein (red), bound to CD4 (yellow) and 17b antibody (blue) provided by Jonathan Stuckey, Vaccine Research Center, NIAID, NIH. The HVTN: Strategic Accomplishments of the First Decade and Beyond Tracey Day, Cecilia Morgan, Adi Ferrara, and Jim Kublin The development of an effective HIV Streamlined Protocol has been streamlining the protocol vaccine is one of humanity’s greatest Development Process development and implementation scientific challenges. In acknowledg- process. This has been achieved largely ing that the path to an effective HIV Before a clinical trial can begin, a through efforts to bring stakeholders vaccine will likely require numerous trial protocol outlining the protocol’s to the table at the appropriate time iterative steps, the HVTN has aimed objectives, target population, and con- and ensure that all support opera- to improve the process of designing, duct must be approved.
    [Show full text]